VERTEX PHARMACEUTICALS INC / MA (VRTX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.50M; Additional Paid in Capital, Common StockUSD $4.51B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $48.50M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.50M; Additional Paid in Capital, Common StockUSD $4.74B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $24.80M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.50M; Additional Paid in Capital, Common StockUSD $5.12B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-15.90M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.50M; Additional Paid in Capital, Common StockUSD $5.01B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-64.50M.
VERTEX PHARMACEUTICALS INC / MA Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Other USD | Noncontrolling Interest, Increase from Sale of Parent Equity Interest USD | Noncontrolling Interest, Increase from Business Combination USD | Noncontrolling Interest, Decrease from Deconsolidation USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $2.50M | $4.51B | $48.50M | $15.69B | $20.25B | 3 month · $173.90M 6 month · $343.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $2.50M | $4.74B | $24.80M | $14.59B | $19.36B | 3 month · $169.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $2.50M | $5.12B | $-15.90M | $13.56B | $18.67B | 12 month · $700.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $2.50M | $5.01B | $-64.50M | $12.37B | $17.32B | 3 month · $199.30M 9 month · $539.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $2.60M | $5.99B | $-101.10M | $11.29B | $17.18B | 3 month · $171.20M 6 month · $340.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $2.60M | $6.17B | $68.10M | $10.25B | $16.50B | 3 month · $169.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $2.60M | $6.67B | $127.80M | $9.61B | $16.41B | 12 month · $709.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $2.60M | $6.91B | $28.80M | $8.69B | $15.63B | 3 month · $188.20M 9 month · $538.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $2.60M | $7.10B | $22.50M | $7.65B | $14.77B | 3 month · $157.00M 6 month · $350.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $2.60M | $7.28B | $17.30M | $11.24B | $18.55B | 3 month · $193.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $2.60M | $7.45B | $-14.30M | $10.14B | $17.58B | 12 month · $583.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $2.60M | $7.34B | $-3.00M | $9.17B | $16.51B | 3 month · $131.70M 9 month · $374.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $2.60M | $7.37B | $-39.80M | $8.14B | $15.47B | 3 month · $119.90M 6 month · $242.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $2.60M | $7.22B | $-13.10M | $7.22B | $14.43B | 3 month · $122.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $2.60M | $7.39B | $800.00K | $6.52B | $13.91B | 12 month · $490.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $2.60M | $7.23B | $97.60M | $5.70B | $13.03B | 3 month · $135.30M 9 month · $379.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $2.60M | $7.10B | $57.50M | $4.77B | $11.93B | 3 month · $113.60M 6 month · $244.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | $2.60M | $6.93B | $11.30M | $3.96B | $10.91B | 3 month · $130.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $2.50M | $6.88B | $15.90M | $3.20B | $10.10B | 12 month · $445.50M | (m) | $10.10B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $0.00 | $2.56M | $7.09B | $11.54M | $2.43B | $9.53B | 3 month · $103.70M 9 month · $326.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $0.00 | $2.59M | $7.64B | $-25.16M | $1.58B | $9.20B | 3 month · $105.90M 6 month · $223.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $0.00 | $2.59M | $7.50B | $-33.30M | $1.51B | $8.98B | 3 month · $117.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $2.60M | $7.89B | $-68.50M | $858.70M | $8.69B | 12 month · $433.10M | (m) | $8.69B | (m) | (m) | (m) | (m) | (m) | 12 month · $-2.91M | (m) |
| 2020-09-30 | $0.00 | $2.60M | $7.92B | $-40.98M | $254.48M | $8.13B | 3 month · $100.49M 9 month · $335.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $0.00 | $2.60M | $7.94B | $-14.12M | $-412.95M | $7.52B | 3 month · $118.12M 6 month · $235.02M | (m) | $7.52B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $0.00 | $2.59M | $7.70B | $13.38M | $-1.25B | $6.46B | 3 month · $116.90M | (m) | $6.46B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $0.00 | $2.59M | $7.94B | $-1.97M | $-1.85B | $6.09B | 12 month · $362.20M | (m) | $6.09B | (m) | (m) | (m) | (m) | (m) | 12 month · $25.52M | (m) |
| 2019-09-30 | $0.00 | $2.57M | $7.67B | $18.85M | $-2.44B | $5.25B | 3 month · $85.96M 9 month · $270.13M | (m) | $5.25B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $0.00 | $2.56M | $7.56B | $-3.20M | $-2.49B | $5.07B | 3 month · $89.94M 6 month · $184.18M | (m) | $5.07B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $0.00 | $2.56M | $7.48B | $6.00M | $-2.76B | (m) | 3 month · $94.24M | (m) | $4.72B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-01-01 | (m) | (m) | (m) | (m) | $-3.03B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | $2.55M | $7.42B | $659.00K | $-2.99B | $4.44B | 12 month · $325.66M | (m) | $4.44B | (m) | (m) | (m) | (m) | (m) | 12 month · $-1.77M | (m) |
| 2018-09-30 | $0.00 | $2.55M | $7.44B | $307.00K | $-4.54B | $2.91B | 3 month · $85.44M 9 month · $246.56M | (m) | $2.93B | (m) | (m) | (m) | (m) | (m) | 9 month · $-7.96M | (m) |
| 2018-06-30 | $0.00 | $2.54M | $7.36B | $-4.61M | $-4.67B | $2.69B | 3 month · $82.52M 6 month · $161.12M | (m) | $2.71B | (m) | (m) | (m) | (m) | (m) | 6 month · $-9.68M | (m) |
| 2018-03-31 | $0.00 | $2.54M | $7.31B | $-39.74M | $-4.88B | $2.40B | 3 month · $78.60M | (m) | $2.43B | (m) | (m) | (m) | (m) | (m) | 3 month · $-6.78M | (m) |
| 2018-01-01 | (m) | (m) | (m) | $-10.62M | $-5.11B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | $2.51M | $7.16B | $-11.57M | $-5.12B | $2.03B | 12 month · $295.64M | $-21.00M | $2.04B | (m) | (m) | (m) | (m) | (m) | 12 month · $-2.65M | (m) |
| 2017-09-30 | $0.00 | $2.50M | $7.03B | $-25.13M | $-5.22B | $1.79B | 9 month · $218.99M | (m) | $1.80B | (m) | (m) | (m) | (m) | (m) | 9 month · $1.40M | (m) |
| 2017-06-30 | $0.00 | $2.48M | $6.81B | $-21.75M | $-5.12B | $1.67B | 6 month · $143.86M | (m) | $1.87B | (m) | (m) | (m) | (m) | (m) | 6 month · $4.71M | (m) |
| 2017-03-31 | $0.00 | $2.46M | $6.62B | $16.02M | $-5.14B | $1.50B | 3 month · $69.79M | (m) | $1.68B | (m) | (m) | (m) | (m) | (m) | 3 month · $3.88M | (m) |
| 2016-12-31 | $0.00 | $2.45M | $6.51B | $21.17M | $-5.37B | $1.16B | 12 month · $241.24M | $-7.90M | $1.34B | (m) | (m) | (m) | (m) | (m) | 12 month · $9.65M | (m) |
| 2016-09-30 | $0.00 | $2.45M | $6.43B | $-3.85M | $-5.41B | $1.02B | 9 month · $181.28M | (m) | $1.21B | (m) | (m) | (m) | (m) | (m) | 9 month · $4.78M | (m) |
| 2016-06-30 | $0.00 | $2.44M | $6.35B | $-3.39M | $-5.37B | $981.35M | 6 month · $119.11M | (m) | $1.17B | (m) | (m) | (m) | (m) | (m) | 6 month · $2.06M | (m) |
| 2016-03-31 | $0.00 | $2.43M | $6.26B | $-4.90M | $-5.30B | $957.08M | 3 month · $56.25M | (m) | $1.12B | (m) | (m) | (m) | (m) | (m) | 3 month · $1.39M | (m) |
| 2015-12-31 | $0.00 | $2.43M | $6.20B | $1.82M | $-5.26B | $939.97M | 12 month · $235.11M | $-2.10M | $1.09B | (m) | (m) | 12 month · $164.32M | 12 month · $164.32M | (m) | 12 month · $4.73M | (m) |
| 2015-09-30 | $0.00 | $2.42M | $6.11B | $1.51M | $-5.19B | $922.15M | 9 month · $189.70M | (m) | $1.08B | (m) | (m) | (m) | 9 month · $164.32M | (m) | 9 month · $3.50M | (m) |
| 2015-06-30 | $0.00 | $2.41M | $5.99B | $-1.71M | $-5.09B | $894.96M | 6 month · $122.68M | (m) | $1.05B | (m) | (m) | (m) | 6 month · $164.32M | (m) | 6 month · $2.60M | (m) |
| 2015-03-31 | $0.00 | $2.40M | $5.88B | $791.00K | $-4.90B | $976.46M | 3 month · $58.27M | (m) | $997.54M | (m) | (m) | (m) | (m) | (m) | 3 month · $1.70M | (m) |
| 2014-12-31 | $0.00 | $2.38M | $5.78B | $917.00K | $-4.71B | $1.08B | 12 month · $178.97M | $-1.00M | $1.10B | (m) | (m) | 12 month · $25.37M | 12 month · $25.37M | (m) | 12 month · $1.56M | (m) |
| 2014-09-30 | $0.00 | $2.38M | $5.68B | $1.16M | $-4.53B | $1.16B | 9 month · $136.06M | (m) | $1.16B | (m) | (m) | (m) | (m) | (m) | 9 month · $427.00K | (m) |
| 2014-06-30 | $0.00 | $2.35M | $5.53B | $-23.00K | $-4.36B | $1.17B | 6 month · $89.47M | (m) | $1.17B | (m) | (m) | (m) | (m) | (m) | 6 month · $17.00K | (m) |
| 2014-03-31 | $0.00 | $2.33M | $5.43B | $-297.00K | $-4.20B | $1.23B | 3 month · $46.79M | (m) | $1.23B | (m) | (m) | (m) | (m) | (m) | 3 month · $-3.00K | (m) |
| 2013-12-31 | $0.00 | $2.32M | $5.32B | $-306.00K | $-3.97B | $1.36B | 12 month · $128.35M | $-300.00K | $1.36B | (m) | (m) | 12 month · $45.45M | (m) | 12 month · $-45.45M | 12 month · $0.00 | (m) |
| 2013-09-30 | $0.00 | $2.31M | $5.27B | $-550.00K | $-4.01B | $1.26B | 9 month · $104.82M | (m) | $1.45B | 9 month · $4.23M | 9 month · $6.70M | (m) | (m) | (m) | 9 month · $0.00 | (m) |
| 2013-06-30 | $0.00 | $2.30M | $5.21B | $-1.23M | $-3.89B | $1.32B | 6 month · $73.31M | (m) | $1.51B | 6 month · $4.23M | 6 month · $6.70M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $0.00 | $2.16M | $4.57B | $-1.15M | $-3.83B | $746.12M | 3 month · $31.57M | (m) | $937.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $0.00 | $2.15M | $4.52B | $-550.00K | $-3.52B | $999.18M | 12 month · $115.54M | $-700.00K | $1.20B | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $115.00M |
| 2012-09-30 | (m) | $2.14M | $4.47B | $-416.00K | $-3.45B | $1.03B | 9 month · $87.54M | (m) | $1.23B | 9 month · $0.00 | 9 month · $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $2.13M | $4.42B | $-673.00K | $-3.39B | $1.04B | 6 month · $59.62M | (m) | $1.21B | 6 month · $0.00 | 6 month · $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $2.09M | $4.25B | $-628.00K | $-3.32B | $930.50M | 3 month · $27.94M | (m) | $1.07B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $0.00 | $2.07M | $4.20B | $-1.05M | $-3.41B | $786.84M | 12 month · $119.27M | $-900.00K | $928.48M | (m) | (m) | (m) | 12 month · $130.49M | (m) | (m) | 12 month · $114.00M |
| 2011-09-30 | (m) | $2.06M | $4.15B | $-945.00K | $-3.57B | $579.76M | 9 month · $90.00M | (m) | $694.15M | (m) | (m) | (m) | 9 month · $132.27M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $2.06M | $4.10B | $-707.00K | $-3.79B | $307.55M | 3 month · $60.29M 6 month · $60.29M | (m) | $412.88M | (m) | (m) | (m) | 3 month · $130.58M 6 month · $130.58M | (m) | (m) | (m) |
| 2011-03-31 | (m) | $2.03M | $4.01B | $-633.00K | $-3.62B | (m) | 3 month · $28.03M | (m) | $391.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $2.02M | $3.95B | $-1.07M | $-3.44B | $503.97M | 12 month · $91.12M | $-1.10M | $503.97M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $112.00M |
| 2010-09-30 | (m) | $2.01M | $3.91B | $-677.00K | $-3.26B | (m) | 9 month · $67.55M | (m) | $650.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | $0.00 | $2.01M | $3.88B | $-558.00K | $-3.06B | (m) | (m) | (m) | $827.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | $0.00 | $2.00M | $3.84B | $-1.08M | $-2.86B | (m) | (m) | (m) | $990.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $0.00 | $1.98M | $3.78B | $-640.00K | $-2.69B | (m) | 12 month · $86.72M | $-600.00K | $1.10B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $57.98M | $27.00K | $238.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $271.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |